Inhibition of replication of hepatitis B virus in transgenic mice following administration of hepatotropic lipoplexes containing guanidinopropyl-modified siRNAs.

[1]  A. Ely,et al.  Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific Promoter , 2014, BioMed research international.

[2]  A. Ely,et al.  Inhibition of HBV replication in vivo using helper-dependent adenovirus vectors to deliver antiviral RNA interference expression cassettes , 2014, Antiviral therapy.

[3]  A. Ely,et al.  Inhibition of hepatitis B virus replication in cultured cells and in vivo using 2'-O-guanidinopropyl modified siRNAs. , 2013, Bioorganic & medicinal chemistry.

[4]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  J. Engels.  Gene silencing by chemically modified siRNAs. , 2013, New biotechnology.

[6]  Alan McLachlan,et al.  Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  D. Scherman,et al.  Reduced in vitro and in vivo toxicity of siRNA-lipoplexes with addition of polyglutamate. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[8]  Darren H. Wakefield,et al.  Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. , 2012, Nucleic acid therapeutics.

[9]  A. Ely,et al.  Synthesis of 2'-O-guanidinopropyl-modified nucleoside phosphoramidites and their incorporation into siRNAs targeting hepatitis B virus. , 2012, Bioorganic & medicinal chemistry.

[10]  E. Keeffe,et al.  Review article: current antiviral therapy of chronic hepatitis B , 2011, Alimentary pharmacology & therapeutics.

[11]  A. Ely,et al.  Countering hepatitis B virus infection using RNAi: how far are we from the clinic? , 2011, Reviews in medical virology.

[12]  D. Scherman,et al.  Anionic polymers for decreased toxicity and enhanced in vivo delivery of siRNA complexed with cationic liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[13]  N. Nishiyama,et al.  Introduction of stearoyl moieties into a biocompatible cationic polyaspartamide derivative, PAsp(DET), with endosomal escaping function for enhanced siRNA-mediated gene knockdown. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Eric B. Roesch,et al.  Inhibition of hepatitis B virus replication in vivo using lipoplexes containing altritol-modified antiviral siRNAs , 2010, Artificial DNA, PNA & XNA.

[15]  Andrew D. Miller,et al.  DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[16]  Jin-Zhi Du,et al.  Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. , 2010, Small.

[17]  D. Scherman,et al.  How to make siRNA lipoplexes efficient? Add a DNA cargo. , 2009, Biochimica et biophysica acta.

[18]  Yukikazu Natori,et al.  Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. , 2009, Molecular pharmaceutics.

[19]  M. Behlke.  Chemical modification of siRNAs for in vivo use. , 2008, Oligonucleotides.

[20]  P. Marion,et al.  Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. , 2008, Human gene therapy.

[21]  A. Ely,et al.  Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Samantha Barichievy,et al.  Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  C. Culmsee,et al.  siRNA delivery by a transferrin‐associated lipid‐based vector: a non‐viral strategy to mediate gene silencing , 2007, The journal of gene medicine.

[24]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[25]  P. Marion,et al.  Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[27]  Judy Lieberman,et al.  Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors , 2005, Nature Biotechnology.

[28]  T. Roskams,et al.  Morphological and biochemical characterization of a human liver in a uPA‐SCID mouse chimera , 2005, Hepatology.

[29]  Henning Urlaub,et al.  Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi , 2002, Cell.

[30]  T. Tuschl,et al.  Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate , 2001, The EMBO journal.

[31]  R. J. Hunter,et al.  Zeta Potential of Highly Charged Thin Double-Layer Systems. , 2001, Journal of colloid and interface science.

[32]  M. Yaniv,et al.  Nuclear Covalently Closed Circular Viral Genomic DNA in the Liver of Hepatocyte Nuclear Factor 1α-Null Hepatitis B Virus Transgenic Mice , 2001, Journal of Virology.

[33]  F. Chisari,et al.  High-level hepatitis B virus replication in transgenic mice , 1995, Journal of virology.

[34]  M. Nassal.  The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly , 1992, Journal of virology.

[35]  E. Wisse,et al.  The liver sieve: Considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of disse , 1985, Hepatology.

[36]  L. Hwang,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 1984, Seminars in liver disease.

[37]  A. Ely,et al.  Use of guanidinopropyl-modified siRNAs to silence gene expression. , 2015, Methods in molecular biology.

[38]  P. Arbuthnot,et al.  Efficient nucleic acid transduction with lipoplexes containing novel piperazine- and polyamine-conjugated cholesterol derivatives. , 2009, Bioorganic & medicinal chemistry letters.

[39]  Dr. Chau Tai-Nin,et al.  Hepatocellular Carcinoma and Hepatitis B Virus , 2006 .

[40]  M. Winters,et al.  A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus , 2003 .

[41]  J. Bruix,et al.  Hepatitis B virus and hepatocellular carcinoma. , 2003, Journal of hepatology.